CA-EAG-LABORATORIES
EAG Laboratories is expanding its medical device testing capabilities with a new 20,000 square-foot laboratory located in St. Louis, Mo.
The new laboratory is a bespoke design to support the requirements of the medical device industry. It increases EAG’s analytical capabilities, allows for improved turnaround times and helps meet evolving requirements from the FDA as well as the European Union Medical Device Regulations (MDR).
Specialty features of the laboratory include:
- A cleanroom designed for particle isolation and identification
- A dedicated medical device polymer analysis laboratory
- State-of the-art instrumentation to support biocompatitility testing of ISO 10993-18 programs for medical devices and combination products
EAG scientists have been investigating and resolving product failures for more than half a century and have a deep understanding of materials and testing procedures. The medical device laboratory expansion allows EAG to leverage that knowledge and apply it toward supporting the growing and vitally important medical device industry.
The St. Louis laboratory is ISO 9001:2015 and ISO 17025 accredited; FDA-registered and DEA Licensed, and offers analytical support in terms of materials characterization, failure analysis, particle identification, contaminant identification, analyte quantitation, and ISO 10993-18 chemical characterization.
About EAG Laboratories
EAG Laboratories is the global leader in materials and engineering sciences and supports thousands of clients with 20+ locations throughout Europe, Asia, and the U.S. For more information visit eag.com. EAG Laboratories’ parent company, Eurofins Scientific, is a multi-billion global leader in scientific testing services with a portfolio of over 200,000 validated analytical methods.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210507005431/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ardian Set to Mobilize Development Finance Institutions (DFIs) With European Investment Bank (EIB), Proparco and British International Investment (BII) for a €100m Commitment for Its Nature-Based Solutions Strategy12.11.2025 17:12:00 CET | Press release
Ardian’s Nature-Based Solutions strategy is dedicated to investing in projects in reforestation, wetlands and mangrove restoration intended to protect biodiversity. The strategy aims at providing carbon credit to corporates in their decarbonisation strategy. It will enable the sequestration of 85 million tons of carbon from the atmosphere over a 40 year’ period. European Investment Bank commits €50m and Proparco €20m and British International Investment intend to commit €10m, reflecting increasing DFIs appetite in the sector. Ardian, a world-leading private investment firm, today announces that it has secured commitment from several Development Finance Institutions (DFIs), the European Investment Bank (EIB) and Proparco. British International Investment (BII) have signaled their intention to provide commitment to the Nature Based Solutions fund. Total fund commitments will stand for a total of c. €100m by year end to Ardian’s Nature-Based Solutions (NBS) strategy. As anchor investors,
ViTAA Medical Secures FDA 510(k) Clearance for AiORTA™ Plan — Marking the First Step in Its Hyper-Precise Aortic Care Platform12.11.2025 16:00:00 CET | Press release
FDA clearance marks a pivotal milestone in ViTAA’s broader AiORTA™ suite, designed to support physicians across the full continuum of aortic care ViTAA Medical Solutions Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for AiORTA™ Plan, the company’s fully automated, hyper-precise aortic surgery planning solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112394413/en/ This clearance represents a key milestone in the evolution of ViTAA’s broader AiORTA™ platform, built to support physicians across the full continuum of aortic care. ViTAA’s additional innovations—AiORTA™ Maps and AiORTA™ Watch—are currently in multicenter clinical studies, progressing rapidly toward future clinical release. A Leap Forward in Aortic Surgery Planning Built to automate key preoperative measurements and streamline aortic case prep, AiORTA™ Plan generates a complete aortic plan in minutes.
Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 202512.11.2025 15:30:00 CET | Press release
– Multiple presentations on vimseltinib for the treatment of Tenosynovial Giant Cell Tumor (TGCT), including encore data from the Phase 3 MOTION study presented in an oral session – – Two posters on DCC-3009 in Gastrointestinal Stromal Tumor (GIST) – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that data from multiple pipeline programs, including long-term and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option, will be presented during the CTOS Annual Meeting 2025, taking place November 12-15 in Boca Raton, Florida. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112742665/en/ “We are excited about the breadth of data we’re presenting at CTOS this year, which underscore the strong progress we continue to sustain across our pipeline,” said Matthew L. Sherman, M.D
Deskpro Launches New Private Help Desk Solution with Private AI Support for Organizations with Strict Security, Compliance, and Data Sovereignty Requirements12.11.2025 15:13:00 CET | Press release
Deskpro Private Eliminates Impossible Choice Between AI Capabilities and Data Security for Organizations Including Financial Services, Healthcare, Aerospace and Defense, and Government Today, Deskpro, provider of the secure AI-powered help desk platform, announced the launch of Deskpro Private, making AI-powered help desk capabilities available to industries with stringent security and compliance requirements for the first time. The new platform delivers flexible private deployment, allowing companies to run their AI-powered help desk entirely within their AWS Virtual Private Cloud (VPC), on-premise enterprise data center, or sovereign cloud. Enterprises can connect to their AI of choice, including commercial, public, private, custom, and open source models, using existing organizational accounts and APIs. This means sensitive data never leaves the organization’s approved security perimeter. With Deskpro, organizations no longer need to sacrifice the measurable ROI from AI capabilities
New Study Reveals Tech Industry Leads AI Adoption in Support Operations at 92%; Regulated Industries Only at 58% Due to Compliance Constraints12.11.2025 15:06:00 CET | Press release
Research Finds Security and Compliance Requirements Are Reshaping Technology Adoption, with Healthcare, Finance, and Government Organizations Facing Deployment Constraints that Technology Companies Avoid Today, Deskpro, provider of the secure AI-powered help desk platform, released results from the State of AI in Support Operations: Balancing Innovation and Compliance report, which quantifies how security and compliance requirements are creating distinct market segments with vastly different AI adoption rates. According to the data, 92% of technology companies are adopting AI for support operations, while companies in regulated industries are significantly lagging behind with a 58% adoption rate. This 34-point gap reflects a significant disconnect: organizations are eager to adopt AI-powered support solutions, but face significant barriers related to data security, compliance and regulatory requirements, and deployment flexibility. While market demand for AI support capabilities exists
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom